

The FDA approves ropeginterferon alfa-2b-njft for essential thrombocythemia, the first new treatment for the rare...

Breast cancer diagnosis taught Dr. Molly Greenwade, an oncologist, lessons on early detection while juggling...

A study in Nature overturns the assumption that longer sleep is universally better for aging....
Read our latest Drug Approvals articles.

Therapeutic phlebotomy is one of the key treatments for managing polycythemia vera risks, helping lower...

Most breast bruises are not linked to breast cancer unless they persist beyond two weeks,...

Doctors reject federal vaccine changes lacking scientific backing as top medical groups like AAP and...

Standard physical tests often fail to diagnose chronic pelvic pain effectively. Learn how brain processing and inflammation play a larger role in diagnosis and




Standard physical tests often fail to diagnose chronic pelvic pain effectively. Learn how brain processing and inflammation play a larger...
Scientists suggest boosting glutathione may slow age-related cellular decline, offering one of the most promising approaches to support long-term health.
Family physicians weigh multiple factors when deciding whether to refer a patient for a hearing assessment, including symptoms and access...
Tirzepatide and semaglutide have similar asthma risks in adults with type 2 diabetes and asthma.
FDA reviews two novel ADHD drug candidates in late-stage development, offering new approaches to treatment.
Doctors reject federal vaccine changes lacking scientific backing as top medical groups like AAP and ACOG defend evidence-based immunization schedules.
Effective strategies for managing challenging patient relationships, focusing on cases where patients reject care or question competence.
The FIB-4 index celebrates 20 years as a non‑invasive tool for spotting advanced liver fibrosis in MASLD, MASH, hepatitis C...
New ATA guidelines for thyroid disease in pregnancy and preconception provide expert updates on testing, hypothyroidism, and iodine intake for...
Noninvasive tests now replace risky liver biopsies for diagnosing metabolic dysfunction-associated steatohepatitis (MASH) and MASLD, offering safer, cost-effect